Indian Immunology Company launches dietary and rubella vaccines for children

Vaccine maker Indian Immunologicals (IIL) has launched meal and rubella vaccine Mabella for children.

(For the day’s top health news, subscribe to our Health Matters newsletter)

Mabella, a live attenuated MR vaccine developed in exclusive collaboration with Polyvac Research Institute in Vietnam, was launched as part of the 25th anniversary celebrations of the Human Biology Institute (HBI), IIL department, Udhagamandalam (Ooty), Tamil Nadu.

Also Read: Explained | India plans to eradicate meals, rubella

The vaccine has been proven safe and effective through extensive human clinical trials. IIL said on November 25 that the launch addresses the urgent need to control deadly food and rubella diseases that claim the lives of around 100,000 children globally.

HBI indigenously developed the country’s “first safe Vero cell rabies vaccine, Abhayrab” that same year, paving the way for government approval, the vaccine maker said in a press release on the work of the unit established in 1998. India to phase out painful nerve tissue vaccine. “Today, Abhayrab is the world’s largest-selling anti-rabies vaccine.” Subsequently, HBI launched a number of children’s vaccines, such as diphtheria-tetanus pertussis, pentavalent vaccine, TT, hepatitis B MR and Td.

K.Anand Kumar, managing director of IIL, said the company has emerged as one of the largest suppliers of human vaccines to the Centre’s universal immunization programme. Deputy General Manager Priyabrata Pattnaik said IIL has adequate infrastructure to meet the national requirements.